Back to search

Article

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib

2021-09-24

Abstract excerpt

<h4>Aim: </h4> The adverse events of the CKD4/6 inhibitor abemaciclib are known to be dose dependent. However, its pharmacokinetics vary among individuals. Abemaciclib is reported to be transported by P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP). Therefore, we evaluated whether ABCB1 and ABCG2 gene polymorphisms could be pharmacokinetic predictive factors of abemaciclib. <h4>Methods:</h4>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
313c7d9c-8dab-5498-9f38-2367bc2eb5a0
DOI
10.22541/au.163250698.89674939/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclibDOI 10.22541/au.163250698.89674939/v1
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.Semantic proximity
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18).Semantic proximity
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.Semantic proximity
ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2Semantic proximity
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and RibociclibSemantic proximity
Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.Semantic proximity
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.Semantic proximity
ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentSemantic proximity
Select a neighboring publication to make it the new centre.